TGA presentation: 2017 Pharmaceutical Society of Australia Conference (PSA17), 30 July 2017

Presentation: Prescription medicines reforms

9 August 2017

Disclaimer

These presentation papers are provided on the TGA's website solely for the purpose of indicating or suggesting what TGA representatives spoke about to the various conferences and seminars to which it relates. The papers are not legislative in nature and should not be taken to be statements of any law or policy in any way.

The Australian Government Department of Health (of which the TGA is a part) advises that (a) the presentation papers should not be relied upon in any way as representing a comprehensive description of regulatory requirements, and (b) cannot guarantee, and assumes no legal liability or responsibility for, the accuracy, currency or completeness of the information contained in the presentation paper.

Presentation

  • Presented by: Adrian Bootes, Assistant Secretary, Prescription Medicine Authorisation Branch, Therapeutic Goods Administration
  • Presented at: 2017 Pharmaceutical Society of Australia Conference (PSA17)
  • Presentation date: 30 July 2017
  • Presentation summary: An overview of recent and current reforms to prescription medicines regulation in Australia

Transcript

Prescription Medicines Reforms

Medsearch App, PI Reformat, Priority Review, Provisional Approval Black Triangle Scheme and Orphans

Adrian Bootes
Assistant Secretary, Prescription Medicine Authorisation Branch, Department of Health

2017 Pharmaceutical Society of Australia Conference, 30 July 2017

Slide 1 - MedSearch™

The trusted source of medicine information in Australia

  • FREE app available from June 2017
  • Consumer Medicine Information (CMI) or Product Information (PI) document
  • Sources directly from the Australian Register of Therapeutic Goods (ARTG)

Slide 2 - MedSearch™ features

Quickly access prescription medicine information from your phone:

  • Simply search the medicine name to find its CMI or PI
  • Favourites - bookmark medicine information in one place
  • Save medicine info documents and view them anytime
  • Share CMI/PI documents with family and carers

Connects consumers, carers, doctors, nurses and pharmacists to trusted and current information about their prescription medicines

Slide 3 - Changes to the Product Information (PI)

  • From January 2018 all new medicines will have a revised format that provides the important product information at the beginning of the PI, such as:
    • Indications
    • Contraindications
    • Warnings
    • Adverse events
  • Transition to this new format will be over 3 years
  • Medicines with new PI information - such as extension of their indication, new safety information - will be available in the new format
  • By end 2020 all medicine PIs will be in the new format

Slide 5 - Expedited pathways

  • Two new 'expedited' pathways for prescription medicines based on the government response to the recommendations of the MMDR review:
    • Priority Review of a complete data dossier within a reduced timeframe in certain circumstances (implemented in July 2017)
    • Provisional Approval on the basis of early data on safety and efficacy, where the immediate availability of the medicine outweighs the risk that more data is required (under development)
  • The key objective of the expedited pathways is to facilitate earlier access to medicines that address unmet clinical needs for Australian consumers, without compromising our standards for safety, efficacy and quality

Slide 4 - Eligibility criteria

The medicine is a new prescription medicine or a new indication

High level eligibility criteria for Priority Review and Provisional Approval:

  • serious condition
  • major therapeutic advance
  • comparison against existing therapeutic goods

Eligibility for:

  • Priority Review will be based on 'substantial evidence'
  • Provisional Approval based on 'promising evidence from early clinical data'

Slide 5 - Priority Review

  • Introduced on 1 July 2017 through legislative and regulation amendments
  • New and flexible business processes to reduce the timeframe for assessing certain medicines with a full data dossier
  • Target of 150 working days for the registration process consistent with benchmarks set by international regulators
  • It is a 'partnership' and exit pathways to a standard pathway exist if the sponsor does not meet requirements for Priority Review
  • Full registration in the Australian Register of Therapeutic Goods (ARTG)

Slide 6 -Priority Review Implementation Plan

June

  • Amendments to the Therapeutic Goods Act changes passed on 19 June 2017

July

  • TGA started to accept notifications of the intent to file/lodge for Priority Review designation applications or requests for pre-designation meetings
  • The new Priority Review regulation came into effect (1 July)
  • TGA published Priority Review guidance prior to 1 July 2017
  • TGA provides a new designation application e-form
  • TGA starts to accept Priority Review designation applications

Aug/Sep

  • First designation decisions under the Priority Review designation process are possible
  • Earliest opportunity to lodge Pre-submission Planning Form (PPF) with valid Priority Review designation
  • TGA starts to accept submissions for registration with valid Priority Review designation for priority evaluation

Dec

  • Ongoing monitoring of the number of submitted designation applications and decision outcomes and the time from designation application lodgment to decision

July 2018

  • The impact of changes will be reviewed considering designation application numbers, designation outcomes and stakeholder feedback. The guidance material will be reviewed and updated if required

Slide 7 - More information on our website

Slide 8 - Provisional Approval pathway

Provisional Approval is currently scheduled to be implemented in the first quarter of 2018 (subject to necessary legislative amendments) and will involve:

  • Allowing the TGA to provide provisional registration on the ARTG in the initial absence of full clinical data on safety and efficacy
  • Provisional registration granted for a specified period of time (currently proposed 2 years with a maximum of 2 extensions of 1-2 years each)
  • Sponsors will be required to collect and submit further clinical data to demonstrate efficacy and safety in order for the product to be granted full registration
  • Enhanced post-market monitoring and surveillance
  • Provisional registration will be subject to the provision of clear advice to consumers and healthcare professionals and any other conditions imposed by the TGA

Slide 9 - Outlook - Provisional Approval pathway

  • We recently conducted public consultation on the implementation arrangements for the proposed Provisional Approval pathway
    • Consultation outcomes will be published on the TGA website shortly
    • Stakeholder feedback will inform legislative amendments and TGA business processes
  • Further targeted consultation will be undertaken with industry on draft guidance for the Provisional Approval pathway later in 2017
  • We will also work closely with consumer and healthcare professional representative groups to ensure appropriate messaging about provisionally registered medicines

Slide 10 - Other reforms - Orphan Drug Program

The objective of the orphan drug program is to provide an incentive to sponsors to bring medicines for a small population to market and make medicines available to patients who would not otherwise be able to access them.

What's changing?

  • EMA alignment
  • Prevalence
  • New criteria
  • Designation validity
  • Transition period
  • Two pathways
  • Documentation

Slide 11 - New dosage form medicine pathway

An orphan designation for a medicine that is a new dosage form:

  • Life-threatening or seriously debilitating condition
  • Not financially viable
  • No refusal to approve overseas
  • Comparison against existing goods

Definition of new dosage form:

  • has the same chemical, biological or radiopharmaceutical active ingredient (or fixed combination of such ingredients) as another medicine that is included in the Register
  • has an indication in common with that other medicine
  • does not have the same dosage form as that other medicine

Benefits small patient populations, e.g. paediatrics

Slide 12 - Criteria comparison

Criteria Priority review Standard orphan New dosage form medicine orphan
Life threatening or seriously debilitating
Comparison against existing therapeutic goods
Major therapeutic advance

Prevalence threshold (now 5/10,000)

OR

Not financially viable

Medical plausibility

Slide 13 - More information on our website

Slide 14 - Black Triangle Scheme

  • Provides a simple means to identify new medicines
  • Encourages the reporting of adverse events associated with their use
  • The symbol and text will appear on the PI and CMI, and TGA-related materials

PI:

▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse events.

CMI:

▼ This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get.

Slide 15 - Black Triangle Scheme - inclusion criteria

  • All new medicines, except:
    • Biosimilars
    • Seasonal influenza vaccines
  • Medicines with a provisional extension of indications
  • Extensions of indication into significantly different conditions or patient groups may be included
    • example. from an oncology to rheumatology indication

Slide 16 - Black Triangle Scheme

  • Provides a simple means to identify new medicines
  • Encourages the reporting of adverse events associated with their use
  • The symbol and text will appear on the PI and CMI, and TGA-related materials

PI:

▼This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse events.

CMI:

▼This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get.

Print version

How to access a pdf document

*Large file warning: Attempting to open large files over the Internet within the browser window may cause problems. It is strongly recommended you download this document to your own computer and open from there.